Is the number of blood products transfused associated with lower survival in children with acute lymphoblastic leukemia?

Pediatric Blood and Cancer

Volumn 57, Issue 2, 2011, Pages 217-223

  Jaime Pérez, José Carlos ^a   Colunga Pedraza, Perla R ^a   Gómez Almaguer, David ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Acute lymphoblastic leukemia; Blood transfusion; Leukoreduction; Microchimerism; Transfusion related immunomodulation

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; FRESH FROZEN PLASMA; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLOOD BANK; BLOOD TRANSFUSION; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CRYOPRECIPITATE; DISEASE REGISTRY; ELECTRONIC MEDICAL RECORD; ERYTHROCYTE CONCENTRATE; EVENT FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOMODULATION; INFANT; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEWBORN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVAL RATE; THROMBOCYTE TRANSFUSION; TREATMENT RESPONSE;

ADOLESCENT; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; CHIMERISM; DISEASE-FREE SURVIVAL; HUMANS; IMMUNOMODULATION; INFANT; INFANT, NEWBORN; LEUKOCYTE REDUCTION PROCEDURES; MULTIVARIATE ANALYSIS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 79958858626     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22957     Document Type: Article

References (39)

1. Blajchman MA. Transfusion immunomodulation or TRIM: What does it mean clinically? Hematology 2005; 10: 208-214.
2. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): An update. Blood Rev 2007; 21: 327-348.
3. Blumberg N, Heal JM. Transfusion and the immune system: A paradigm shift in progress? Transfusion 1995; 35: 879-883.
4. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: Proven beyond a reasonable doubt. Transfusion 2005; 45: 33S-39S; discussion 39S-40S.
5. Kirkley SA, Cowles J, Pellegrini VD, Jr., et al. Cytokine secretion after allogeneic or autologous blood transfusion. Lancet 1995; 345: 527.
6. Jensen LS, Andersen AJ, Christiansen PM, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992; 79: 513-516.
7. Blumberg N, Heal JM. Transfusion and recipient immune function. Arch Pathol Lab Med 1989; 113: 246-253.
8. Brunson ME, Alexander JW. Mechanisms of transfusion-induced immunosuppression. Transfusion 1990; 30: 651-658.
9. Ghio M, Contini P, Mazzei C, et al. Soluble HLA class I, HLA class II, and Fas ligand in blood components: A possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999; 93: 1770-1777.
10. Evans PC, Lambert N, Maloney S, et al. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999; 93: 2033-2037.
11. Reed W, Lee TH, Norris PJ, et al. Transfusion-associated microchimerism: A new complication of blood transfusions in severely injured patients. Semin Hematol 2007; 44: 24-31.
12. Utter GH, Reed WF, Lee TH, et al. Transfusion-associated microchimerism. Vox Sang 2007; 93: 188-195.
13. Simone JV. Use of fresh blood components during intensive combination therapy of childhood leukemia. Cancer 1971; 28: 562-565.
14. Freiberg A, Hancock M, Kunkel K. Transfusions and risk of failure in childhood acute lymphoblastic leukemia. Leukemia 1994; 8: 1220-1223.
15. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
16. Schultz KR, Pullen DJ, Sather HN, et al. Risk- and response-based classification of childhood B-precursor acute lymphoblastic leukemia: A combined analysis of prognostic markers from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). Blood 2007; 109: 926-935.
17. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol 1996; 14: 18-24.
18. Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukaemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124: 33-46.
19. Landers DF, Hill GE, Wong KC, et al. Blood transfusion-induced immunomodulation. Anesth Analg 1996; 82: 187-204.
20. Burrows L, Tartter P. Effect of blood transfusions on colonic malignancy recurrent rate. Lancet 1982; 2: 662.
21. Lapierre V, Auperin A, Tiberghien P. Transfusion-induced immunomodulation following cancer surgery: Fact or fiction? J Natl Cancer Inst 1998; 90: 573-580.
22. Spahn DR, Casutt M. Eliminating blood transfusions: New aspects and perspectives. Anesthesiology 2000; 93: 242-255.
23. Bordin JO, Heddle NM, Blajchman MA. Biologic effects of leukocytes present in transfused cellular blood products. Blood 1994; 84: 1703-1721.
24. d'Almeida MS, Jagger J, Duggan M, et al. A comparison of biochemical and functional alterations of rat and human erythrocytes stored in CPDA-1 for 29 days: Implications for animal models of transfusion. Transfus Med 2000; 10: 291-303.
25. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest 2005; 127: 295-307.
26. Stack G, Baril L, Napychank P, et al. Cytokine generation in stored, white cell-reduced, and bacterially contaminated units of red cells. Transfusion 1995; 35: 199-203.
27. Stack G, Snyder EL. Cytokine generation in stored platelet concentrates. Transfusion 1994; 34: 20-25.
28. Bury TB, Corhay JL, Radermecker MF. Histamine-induced inhibition of neutrophil chemotaxis and T-lymphocyte proliferation in man. Allergy 1992; 47: 624-629.
29. Dellinger EP, Anaya DA. Infectious and immunologic consequences of blood transfusion. Crit Care 2004; 8: S18-S23.
30. Prins HA, Houdijk AP, Nijveldt RJ, et al. Arginase release from red blood cells: Possible link in transfusion induced immune suppression? Shock 2001; 16: 113-115.
31. Davenport RD. An introduction to chemokines and their roles in transfusion medicine. Vox Sang 2009; 96: 183-198.
32. Cognasse F, Boussoulade F, Chavarin P, et al. Release of potential immunomodulatory factors during platelet storage. Transfusion 2006; 46: 1184-1189.
33. Blumberg N, Spinelli SL, Francis CW, et al. The platelet as an immune cell-CD40 ligand and transfusion immunomodulation. Immunol Res 2009; 45: 251-260.
34. Slichter SJ. Evidence-based platelet transfusion guidelines. Hematology Am Soc Hematol Educ Program 2007; 172-178.
35. King KE, Shirey RS, Thoman SK, et al. Universal leukoreduction decreases the incidence of febrile nonhemolytic transfusion reactions to RBCs. Transfusion 2004; 44: 25-29.
36. Bordin JO, Fabron A, Jr. Clinical applications of leukocyte filters. Rev Assoc Med Bras 1997; 43: 205-208.
37. Wu Y, Zou S, Cable R, et al. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Transfusion 2009; 50: 776-786.
38. Vamvakas EC, Blajchman MA. Universal WBC reduction: The case for and against. Transfusion 2001; 41: 691-712.
39. van de Watering LM, Hermans J, Houbiers JG, et al. Beneficial effects of leukocyte depletion of transfused blood on postoperative complications in patients undergoing cardiac surgery: A randomized clinical trial. Circulation 1998; 97: 562-568.